FOLFIRINOX as induction treatment in rectal cancer patients with synchronous metastases: Results of the FFCD 1102 phase II trial

The optimal therapeutic strategy in patients with rectal cancer and synchronous unresectable metastases remains unknown. We evaluated the efficacy of FOLFIRINOX induction therapy in this setting.

Source: European Journal of Cancer - October 18, 2018 Category: Cancer & Oncology Authors: J.B. Bachet, O. Lucidarme, C.B. Levache, E. Barbier, J.L. Raoul, T. Lecomte, C. Desauw, F. Brocard, S. Pernot, G. Breysacher, J.P. Lagasse, F. Di Fiore, P.L. Etienne, O.J.M. Dupuis, A. Aleba, C. Lepage, J. Taieb, for FFCD 1102 investigators Tags: Original Research Source Type: research